What is Standigm?
Founded in 2015 and headquartered in Seoul, Standigm is at the forefront of applying artificial intelligence to drug discovery. The company boasts over 20 preclinical pipelines across diverse therapeutic areas, leveraging its proprietary AI platforms. Standigm's full-stack, AI-driven industrializing drug discovery model includes DarkMolFactory for automated molecular design, Standigm ASK for target discovery, Standigm BEST for lead selection, and Standigm Insight for drug repurposing. This comprehensive suite of technologies aims to revolutionize the efficiency and effectiveness of bringing new medicines to market.
How much funding has Standigm raised?
Standigm has raised a total of $56M across 2 funding rounds:
Angel/Seed
$11.5M
Other Financing Round
$44.5M
Angel/Seed (2019): $11.5M, investors not publicly disclosed
Other Financing Round (2021): $44.5M led by SKS PE, Asset One, Daishin Private Equity, InterVest, and KDB Bank
Key Investors in Standigm
KDB Bank
KDB Bank, with a domain suggesting a focus on Uzbekistan, likely participated in this strategic investment to support Standigm's expansion and technological advancement in the AI drug discovery sector.
InterVest
InterVest, a notable investment firm, has provided backing to Standigm, signaling confidence in the company's innovative AI drug discovery solutions and its potential for significant market impact.
Daishin Private Equity
Daishin Private Equity has invested in Standigm, recognizing the company's strong position in the AI-driven drug discovery market and its robust pipeline of preclinical assets.
What's next for Standigm?
With substantial enterprise-level capital and a recent strategic investment, Standigm is well-positioned to further scale its AI-driven drug discovery operations. The company's focus on automating critical stages of the pharmaceutical R&D process, from target identification to lead optimization, suggests a trajectory towards expanding its preclinical pipeline and potentially forging new partnerships. Continued investment in its AI platforms and the expansion of its therapeutic areas are anticipated as Standigm aims to solidify its leadership in the competitive biotech landscape.
See full Standigm company page
